Stockscreener 앱 받기
217.72
0.42%
-0.91
전일 마감가:
$218.63
열려 있는:
$219.02
하루 거래량:
7.60M
Relative Volume:
1.15
시가총액:
$384.67B
수익:
$62.82B
순이익/손실:
$3.60B
주가수익비율:
107.39
EPS:
2.0274
순현금흐름:
$19.98B
1주 성능:
+0.94%
1개월 성능:
+6.78%
6개월 성능:
-4.38%
1년 성능:
+17.29%
1일 변동 폭
$214.90
$219.60
1주일 범위
$211.36
$219.60
52주 변동 폭
$181.73
$244.81
애브비 Stock (ABBV) Company Profile
명칭
Abbvie Inc
전화
(847) 932-7900
주소
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Compare ABBV vs LLY, JNJ, MRK, AZN
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
217.72 | 386.27B | 62.82B | 3.60B | 19.98B | 2.0274 |
LLY
Lilly Eli Co
|
1,105.00 | 1.00T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
225.33 | 555.59B | 96.36B | 21.04B | 17.80B | 8.6488 |
MRK
Merck Co Inc
|
118.72 | 296.11B | 65.51B | 8.93B | 14.12B | 3.5532 |
AZN
Astrazeneca Plc
|
185.67 | 287.42B | 60.48B | 10.40B | 8.05B | 3.3297 |
애브비 Stock (ABBV) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-21 | 개시 | Canaccord Genuity | Buy |
| 2026-02-25 | 개시 | RBC Capital Mkts | Outperform |
| 2026-02-20 | 개시 | Barclays | Overweight |
| 2026-01-08 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2026-01-07 | 재개 | UBS | Neutral |
| 2025-12-10 | 업그레이드 | HSBC Securities | Hold → Buy |
| 2025-11-13 | 개시 | Scotiabank | Sector Outperform |
| 2025-11-04 | 다운그레이드 | DZ Bank | Buy → Hold |
| 2025-10-14 | 다운그레이드 | Erste Group | Buy → Hold |
| 2025-10-01 | 다운그레이드 | HSBC Securities | Buy → Hold |
| 2025-09-17 | 업그레이드 | Berenberg | Hold → Buy |
| 2025-08-12 | 재개 | Piper Sandler | Overweight |
| 2025-08-07 | 업그레이드 | Daiwa Securities | Neutral → Outperform |
| 2025-05-14 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2025-04-22 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-12-10 | 재개 | BofA Securities | Neutral |
| 2024-12-05 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2024-11-22 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-11-15 | 개시 | Wolfe Research | Outperform |
| 2024-11-04 | 업그레이드 | Argus | Hold → Buy |
| 2024-10-17 | 개시 | Bernstein | Mkt Perform |
| 2024-06-05 | 업그레이드 | HSBC Securities | Hold → Buy |
| 2024-05-17 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-01-29 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2023-12-18 | 다운그레이드 | HSBC Securities | Buy → Hold |
| 2023-12-11 | 업그레이드 | Goldman | Neutral → Buy |
| 2023-11-09 | 개시 | Deutsche Bank | Hold |
| 2023-10-30 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2023-10-20 | 재개 | UBS | Neutral |
| 2023-09-29 | 개시 | Raymond James | Outperform |
| 2023-07-25 | 개시 | William Blair | Mkt Perform |
| 2023-07-14 | 개시 | HSBC Securities | Buy |
| 2023-04-05 | 다운그레이드 | Argus | Buy → Hold |
| 2023-03-01 | 개시 | Guggenheim | Buy |
| 2023-02-22 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2023-02-10 | 업그레이드 | SVB Securities | Underperform → Market Perform |
| 2022-11-18 | 개시 | Credit Suisse | Outperform |
| 2022-11-08 | 다운그레이드 | Societe Generale | Buy → Hold |
| 2022-08-01 | 다운그레이드 | Atlantic Equities | Overweight → Neutral |
| 2022-05-23 | 개시 | SVB Leerink | Underperform |
| 2022-05-06 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2022-04-06 | 재개 | Morgan Stanley | Overweight |
| 2022-02-28 | 다운그레이드 | UBS | Buy → Neutral |
| 2022-02-03 | 재확인 | BMO Capital Markets | Outperform |
| 2022-02-03 | 재확인 | Barclays | Equal Weight |
| 2022-02-03 | 재확인 | BofA Securities | Neutral |
| 2022-02-03 | 재확인 | Goldman | Neutral |
| 2022-01-13 | 개시 | Redburn | Buy |
| 2022-01-12 | 재확인 | BMO Capital Markets | Outperform |
| 2021-12-09 | 재개 | Wells Fargo | Overweight |
| 2021-11-23 | 업그레이드 | Societe Generale | Hold → Buy |
| 2021-07-27 | 재개 | Truist | Buy |
| 2021-04-07 | 재개 | RBC Capital Mkts | Outperform |
| 2020-11-10 | 재개 | Bernstein | Outperform |
| 2020-09-29 | 개시 | Berenberg | Hold |
| 2020-06-23 | 업그레이드 | Atlantic Equities | Neutral → Overweight |
| 2020-06-09 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2020-06-02 | 업그레이드 | Argus | Hold → Buy |
| 2020-05-18 | 재개 | BofA/Merrill | Neutral |
| 2020-05-12 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2020-05-11 | 재개 | Morgan Stanley | Overweight |
| 2020-04-20 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-03-23 | 다운그레이드 | Societe Generale | Buy → Hold |
| 2020-02-27 | 개시 | Barclays | Equal Weight |
| 2020-02-06 | 개시 | Mizuho | Buy |
| 2020-01-07 | 개시 | RBC Capital Mkts | Sector Perform |
| 2019-12-26 | 재확인 | Cowen | Outperform |
| 2019-09-26 | 업그레이드 | Citigroup | Neutral → Buy |
| 2019-08-20 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2019-06-27 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
| 2019-06-26 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2019-05-28 | 개시 | Goldman | Neutral |
| 2019-04-29 | 업그레이드 | BMO Capital Markets | Underperform → Market Perform |
모두보기
애브비 주식(ABBV)의 최신 뉴스
AbbVie Inc. stock (US00287Y1091): FDA approval for DECNUPAZ and major Norges Bank stake highlight on - AD HOC NEWS
AbbVie Inc. stock (US00287Y1091): EU label expansion for Venclyxto puts oncology focus in the spotli - AD HOC NEWS
AbbVie (ABBV) Up 3.5% Since Last Earnings Report: Can It Continue? - Yahoo Finance
AbbVie Announces European Commission Authorization of Expanded Label for VENCLYXTO® to Include Additional Combinations in Previously Untreated Chronic Lymphocytic Leukemia - Investing News Network
AbbVie (ABBV) Expands Venclyxto Label for Chronic Lymphocytic Le - GuruFocus
AbbVie Stock: Is ABBV Outperforming the Healthcare Sector? - Barchart.com
Abbvie gets EU approval for expanded Venclyxto label in CLL By Investing.com - Investing.com Canada
AbbVie gets EU approval for expanded VENCLYXTO cancer drug combinations - StreetInsider
European Commission okays all-oral VENCLYXTO combos with time off treatment - Stock Titan
AbbVie Inc stock (US00287Y1091): shares edge higher in New York after JPMorgan adjusts outlook - AD HOC NEWS
AB Sustainable Global Thematic Portfolio's AbbVie Inc(ABBV) Holding History - GuruFocus
AbbVie Inc. stock outperforms competitors on strong trading day - MarketWatch
AbbVie’s ADC Strategy Notches Another Win With FDA Approval in Ultra-Rare Blood Cancer - MedCity News
Future of ADCs - AbbVie
AbbVie Wins FDA Nod for Decnupaz for Rare Blood Cancer Indication - Yahoo Finance
VHT vs. XBI: Vanguard Health Care ETF Tops SPDR Biotech in Yield and Cost - The Motley Fool
FDA greenlights AbbVie's new drug against rare blood cancer - medwatch.com
FDA clears AbbVie’s Decnupaz for rare blood cancer - The Pharma Letter
ABBV Stock Price, Quote & Chart | ABBVIE INC (NYSE:ABBV) - ChartMill
AbbVie, Inc. Shs Thailand Depositary Receipts Repr 1 Sh Trade Ideas — SET:ABBV80 - TradingView
US FDA approves AbbVie's rare blood cancer drug - Reuters
AbbVie (ABBV) Receives FDA Approval for Groundbreaking BPDCN Tre - GuruFocus
AbbVie receives FDA approval for BPDCN blood cancer treatment By Investing.com - Investing.com Australia
Ironwood, AbbVie win US label expansion for Linzess in pediatric constipation - MSN
FDA clears first outpatient BPDCN antibody-drug conjugate for rare blood cancer - Stock Titan
AbbVie (ABBV) Secures FDA Approval for Decnupaz in Rare Blood Ca - GuruFocus
US FDA approves AbbVie’s rare blood cancer drug - WKZO
AbbVie Inc. stock (US00287Y1091): Dividend strength and immunology pipeline in focus - AD HOC NEWS
AbbVie (ABBV) Receives FDA Approval for Decnupaz in Rare Cancer Treatment - GuruFocus
Henri Louw Promoted to Vice President, Business HR – Corporate Staff Functions at AbbVie - hrtoday.in
How Did AbbVie's Oncology Portfolio Perform in Q1 Despite Headwinds? - TradingView
Ironwood, AbbVie win U.S. label expansion for Linzess in pediatric constipation - Seeking Alpha
Goldman Sachs, Deckers Outdoor And A Health Care Stock: CNBC's 'Final Trades' - Benzinga
Piper Sandler Raises Price Target on AbbVie (ABBV) Amid Strong IBD Pipeline Progress - Insider Monkey
Free cash flow of AbbVie, Inc. Shs Cert Deposito Arg Repr 0.1 – BCBA:ABBV.CI - TradingView
Total equity of AbbVie, Inc. Shs Cert Deposito Arg Repr 0.1 – BCBA:ABBV.CI - TradingView
Total assets of AbbVie, Inc. Shs Cert Deposito Arg Repr 0.1 – BCBA:ABBV.CI - TradingView
AbbVie, Inc. Shs Cert Deposito Arg Repr 0.1 Balance Sheet – BCBA:ABBV.CI - TradingView
Operating expenses (excl. COGS) of AbbVie, Inc. Shs Cert Deposito Arg Repr 0.1 – BCBA:ABBV.CI - TradingView
AbbVie, Inc. Shs Cert Deposito Arg Repr 0.1 Dividends – BCBA:ABBV.CI - TradingView
Price to earnings ratio of AbbVie, Inc. Shs Cert Deposito Arg Repr 0.1 – BCBA:ABBV.CI - TradingView
AbbVie Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
AbbVie (NYSE: ABBV) Form 144: Director proxy to sell $2.78M in shares - Stock Titan
AbbVie Picks North Carolina for Campus - Advanced Manufacturing
Final Trades: AbbVie, Deckers and Goldman Sachs - CNBC
GE Vernova, Estée Lauder, AbbVie: CNBC's 'Final Trades'AbbVie (NYSE:ABBV), Archer-Daniels-Midland (NYS - Benzinga
AbbVie Inc. stock (US00287Y1091): pharma heavyweight between immunology strength and patent reset - AD HOC NEWS
AbbVie Inc. (ABBV) Stock Analysis: Unraveling a 17% Potential Upside Amid Robust Buy Ratings - DirectorsTalk Interviews
What's the Better Dividend Stock Today: AbbVie or Pfizer? - Yahoo Finance
AbbVie Expands European Reach As Investors Weigh Dividend Support - Yahoo Finance
Hikari Power Ltd's AbbVie Inc(ABBV) Holding History - GuruFocus
애브비 (ABBV) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.98%
0.18%
자본화:
|
볼륨(24시간):